ADA 2017: Evaluating Cardiovascular Safety of Antidiabetic Agents

Cardiovascular risk/benefit profiles of pioglitazone and the SGLT2 inhibitor class are summarized, based on reports at ADA 2017.

Source: ConsultantLive - June 14, 2017 Category: Internal Medicine Authors: Kenneth J. Bender, PharmD, MA Tags: Conferences/ADA 2017 Diabetes Diabetes Type 2 Source Type: news